This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Philippe Humbert, MD, PhD
Department of Dermatology University Hospital 2 Place Saint-Jacques 25030 Besançon Cedex, France

François Aubin, MD, PhD; Jean Louis Dupond, MD
Besançon

Emmanuel Delaporte, MD
Lille, France

Arch Dermatol. 1995;131(7):850-851.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

We read the recent case report by Hulshof et al¹ in the October 1994 issue of the ARCHIVES with interest. The authors described three patients with generalized morphea who were treated with calcitriol (1,25-dihydroxyvitamin D₃) in an oral dose of 0.5 to 0.75 µg per day. After 3 to 7 months of treatment, the authors observed a beneficial effect on joint mobility and skin extensibility. Since our first report in 1990² demonstrating the beneficial effect of oral calcitriol in local- ized scleroderma, we conducted a study in 11 patients with systemic sclerosis and seven patients with morphea that also showed the efficacy of oral calcitriol. To date, after a 2- to 36-month treatment period, we confirm our promising data, as published in two recent reports.^3-5 Taken together, these results suggest that a high dose of oral calcitriol (mean dose, 1.75 µg/d) may be a useful therapeutic . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?